Sderot HaMeginim 32, Haifa, Israel

  • Dr. Shady Hassan, Chief Executive Officer, Co-Founder
  • Daniel Aronovich, Chief Technology Officer, Co-Founder
  • Rafi Gidron, Chairman of the Board, Co-Founder
  • Maura Rosenfeld, Chief Business Development Officer
  • Hazar Abas, VP R&D
What We Do?

Healthymize allows early diagnosis and treatment of COPD exacerbations and thus reduces the number of emergency department visits and hospitalizations. Healthymize is utilizing cutting edge signal processing, machine learning and artificial intelligence algorithms for a personalized speech monitoring of COPD patients through a running in the background mobile app that analyzes the patients' voice during regular voice calls without interfering with their daily routines. COPD is a very common chronic respiratory disease, predicted by the World Health Organization to become the third leading cause of death. Over 5% of the world population is diagnosed as COPD patients. COPD exacerbations are COPD worsening episodes characterized by shortness of breath, cough, and sputum production. Delayed diagnosis and treatment of these symptoms often results in severe exacerbations requiring hospitalization.

Industry / Domain

The burden of COPD on patients, their families, healthcare systems and society continues to grow worldwide. Total medical costs attributable to COPD were estimated to be $72.7 billion in 2010. These costs continue to rise, with an estimated 53% increase forecasted by 2020. According to WHO estimates, 65 million people have moderate to severe COPD. By monitoring those patients, Healthymize total addressable market (TAM) is $7.8B annually.